Text Size
198 studies found for:    "Expanded Access" [STUDY-TYPES]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Approved for marketing Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Available PFO ACCESS Registry
Conditions: Patent Foramen Ovale;   Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
3 Temporarily not available Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
4 Available Uridine Triacetate as an Antidote for Patients at Excess Risk of 5-Fluorouracil (5-FU) Toxicity Due to Overdosage or Impaired Elimination
Conditions: Toxicity Due to Chemotherapy;   Impaired 5FU Elimination
Intervention: Drug: uridine triacetate
5 No longer available Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen
6 No longer available This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Intervention: Drug: Plerixafor
7 Available BMN 110 US Expanded Access Program
Conditions: Mucopolysaccharidosis IVA;   Morquio A Syndrome;   MPS IVA
Intervention: Drug: BMN 110
8 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1
9 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders
Intervention: Drug: triheptanoin
10 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
11 No longer available Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: stiripentol
12 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
13 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
14 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
15 Unknown † Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
16 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
17 Available Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs.
Condition: Acute Myocardial Infarction
Intervention: Drug: Bivalirudin
18 No longer available Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
Conditions: Hepatitis B;   Chronic Disease
Intervention: Drug: Entecavir
19 Approved for marketing Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
Condition: Autologous Stem Cell Transplant
Intervention: Drug: AMD3100 + G-CSF
20 No longer available Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment
Condition: Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
Intervention: Behavioral: questionnaire
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years